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  Cyclophosphamide （Endoxan） 700 mg一一100e mg was admini，stered by drip infusion on an out－
patient basis， at an interval of 3一一4 weeks to 13 v． atients confirmed to have clinical stage D prostatic
cancer． All of the cancers were progressing and had failed to respond to endocrine therapy or were
relapse cases． The following results were obtained．
  Aqcording to Karnofsky’s efficacy evaluatlon standards， 1 case was 1－B， 4 cases were 1－A， 1 case
was O－B， 2 cases were O－A， and 5 cases were 0－O． Five cases （38．50／o） showed objective responses，
and 3 cases showed subjective responses． According to NPCP ellficacy evaluation standards， there
was partial regression in 1 case and progression in 5 cases； and， 7 cases were stable． The effective
rate was 61．50／． （8 out of 13）， when stable or better was judged as effective．
  As to the principal toxicity of Endoxan， reduction of WBC to 3000一一4000fmm3 w4s noted in
5 cases， and gastrointestinal symptoms were seen in 11 cases． But these were mild； and， no treatment
was considered necessary．






 著者もantiandrogen thcrapy d）臨床的効果が期待
できなくなったs亡age D前立腺癌に対し1米国Nation－
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Table 1． Caracteristics of 13 patients
Case




























































9 s．y． 70 WDADESP bone
10 y．o． 66 PDAcastrationDESP
lymph node
bone
11 K．M． 68 MDAcastrationDESP bone
12 K．S． 64 MDADESP bone
13．， N．M． 73 MDAca＄tration bone
PDA ： poorly differentiated adenocarcinoma
MDA ： moderately differentiated adenoearcinoma
WDA ： weil differentiated adenocarcinoma


































           Perforrnance
Relaps Response Status






















































































































｝こobjective responseカ｛， 3｛列 （23．1％） にsubjective
』responseが得られ，これらを合せると13例中8例
（61，5％）に何らかの臨床的改善が認められた．
 NPCP効果判定基準ではpartial regression 1例，





















Fig． 1． Computed tomography of case No． 4
    a） CT at prior chemotheaapy of
     endoxan
    b） CT 2 years after initial evaluation
1130
症例ではPSの改善を認めていない．
副  作  用














Table 3． Toxicity of cyclophosphamide































 しかし，米国＞eterans administration co－operative























































































 2．NPCP効果判定基準ではpartial regression l
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